See more : AI Technology Group Inc. (AIPG) Income Statement Analysis – Financial Results
Complete financial analysis of Vascular Biogenics Ltd. (VBLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vascular Biogenics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Oscar Properties Holding AB (publ) (OP-PREFB.ST) Income Statement Analysis – Financial Results
- Silver One Resources Inc. (SLVRF) Income Statement Analysis – Financial Results
- Guangzhou Sanfu New Materials Technology Co.,Ltd (688359.SS) Income Statement Analysis – Financial Results
- PT Selamat Sempurna Tbk (SMSM.JK) Income Statement Analysis – Financial Results
- G R Infraprojects Limited (GRINFRA.NS) Income Statement Analysis – Financial Results
Vascular Biogenics Ltd. (VBLT)
About Vascular Biogenics Ltd.
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 658.00K | 768.00K | 922.00K | 562.00K | 585.00K | 13.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 104.00K | 365.00K | 394.00K | 163.00K | 235.00K | 340.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 554.00K | 403.00K | 528.00K | 399.00K | 350.00K | 13.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 84.19% | 52.47% | 57.27% | 71.00% | 59.83% | 97.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 21.65M | 22.70M | 19.66M | 15.47M | 15.94M | 17.77M | 12.45M | 11.20M | 10.97M | 13.51M | 10.57M |
| General & Administrative | 11.75M | 7.70M | 5.36M | 4.83M | 5.15M | 5.80M | 3.79M | 3.64M | 3.77M | 2.41M | 1.89M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 397.00K | 562.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.75M | 7.70M | 5.36M | 4.83M | 5.55M | 6.36M | 3.79M | 3.64M | 3.77M | 2.41M | 1.89M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 115.00K | 70.00K | 0.00 | 42.00K | 34.00K | 33.00K | 43.00K | 12.00K |
| Operating Expenses | 33.41M | 30.40M | 25.01M | 20.41M | 21.56M | 24.18M | 16.28M | 14.87M | 14.78M | 15.96M | 12.47M |
| Cost & Expenses | 33.51M | 30.76M | 25.41M | 20.58M | 21.79M | 24.52M | 16.28M | 14.87M | 14.78M | 15.96M | 12.47M |
| Interest Income | 634.00K | 120.00K | 363.00K | 870.00K | 908.00K | 335.00K | 263.00K | 100.00K | 15.00K | 27.00K | 236.00K |
| Interest Expense | 85.00K | 44.00K | 105.00K | 313.00K | 0.00 | 0.00 | 0.00 | 117.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.69M | 120.00K | 1.56M | 2.58M | 1.16M | 156.00K | 130.00K | 122.00K | 135.00K | 169.00K | 197.00K |
| EBITDA | -31.16M | -29.88M | -22.93M | -17.43M | -19.93M | -10.71M | -16.17M | -14.65M | -14.35M | -16.00M | -12.29M |
| EBITDA Ratio | -4,735.71% | -3,890.10% | -2,486.55% | -3,101.42% | -3,406.67% | -77.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.85M | -30.00M | -24.48M | -20.01M | -21.21M | -10.66M | -16.28M | -14.87M | -14.78M | -15.96M | -12.47M |
| Operating Income Ratio | -4,992.86% | -3,905.73% | -2,655.42% | -3,561.21% | -3,625.13% | -76.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 549.00K | 76.00K | 258.00K | 557.00K | 749.00K | 517.00K | 273.00K | -17.00K | -2.63M | -1.41M | 244.00K |
| Income Before Tax | -32.30M | -29.92M | -24.23M | -19.46M | -20.46M | -10.14M | -16.00M | -14.89M | -17.41M | -17.37M | -12.23M |
| Income Before Tax Ratio | -4,909.42% | -3,895.83% | -2,627.44% | -3,462.10% | -3,497.09% | -73.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -85.00K | -1.21M | 105.00K | 313.00K | -749.00K | -517.00K | -273.00K | 17.00K | 2.63M | 1.41M | -244.00K |
| Net Income | -32.22M | -28.71M | -24.33M | -19.77M | -20.46M | -10.14M | -16.00M | -14.89M | -17.41M | -17.37M | -12.23M |
| Net Income Ratio | -4,896.50% | -3,738.02% | -2,638.83% | -3,517.79% | -3,497.09% | -73.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.42 | -0.41 | -0.56 | -0.55 | -0.62 | -0.37 | -0.64 | -0.73 | -3.09 | -1.44 | -1.01 |
| EPS Diluted | -0.42 | -0.41 | -0.56 | -0.55 | -0.62 | -0.37 | -0.64 | -0.73 | -3.09 | -1.44 | -1.01 |
| Weighted Avg Shares Out | 77.55M | 69.33M | 43.67M | 35.88M | 32.97M | 27.40M | 24.97M | 20.31M | 5.63M | 12.05M | 12.05M |
| Weighted Avg Shares Out (Dil) | 77.55M | 69.33M | 43.67M | 35.88M | 32.97M | 27.40M | 24.97M | 20.31M | 5.63M | 12.05M | 12.05M |
Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Vascular Biogenics' Ovarian Cancer Gene Therapy Shows Response Rate Of Over 58%
VBL Therapeutics: A Speculative Play With An Enticing Risk-Reward Profile
Vascular Biogenics' Ovarian Cancer Gene Therapy Study To Continue, Recommends An Independent Committee
VBLT Stock Price Increases Over 10% Pre-Market: Why It Happened
VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients
VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC
VBL Therapeutics Announces First Patient in Europe in the OVAL Trial
VBL Therapeutics Announces Insider Buying
Source: https://incomestatements.info
Category: Stock Reports